Wan Huh

Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial

Ju‐Hyun An, Ben C.B. Ko, H. Namkung, Hyun‐Woo Lim et autres

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors are widely used in human medicine for their insulin-independent glucose-lowering effects. However, their clinical efficacy and safety for managing diabetes mellitus in dogs have not been established. This study aimed to evaluate the efficacy and safety of …

kr, Éthiopie, pr (code pays fourni par la source)

Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study

Ju‐Hyun An, Hansol Choi, Ji‐Soo Choi, Hyun‐Woo Lim et autres

BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of anti-hyperglycaemic agents. OBJECTIVE: This study aimed to evaluate the safety and the adjuvant glycaemic control effect of an SGLT2 inhibitor, DWP16001, in diabetic dogs receiving insulin treatment. METHODS: Nineteen diabetic dogs receiving …

kr (code pays fourni par la source)

The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter ‐2 inhibitor, in type 2 diabetes

Sae Im Jeong, Mu Seong Ban, Jun Gi Hwang, Min Kyu Park et autres

Abstract Aims To explore the effect of renal function on the pharmacokinetic (PK) and pharmacodynamic (PD) profile and safety of enavogliflozin, a selective sodium‐glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes mellitus (T2DM). Methods An open‐label, two‐part clinical trial …

kr (code pays fourni par la source)

Author response for "The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter ‐2 inhibitor, in type 2 diabetes"

Sae Im Jeong, Mu Seong Ban, Jun Gi Hwang, Min Kyu Park et autres

A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study

Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee et autres

AIM: To evaluate the long-term safety and efficacy of enavogliflozin 0.3 mg/day added to metformin in patients with type 2 diabetes mellitus. MATERIALS AND METHODS: After 24 weeks of a randomized, double-blind treatment period with enavogliflozin 0.3 mg/day (n = 101) or …

kr (code pays fourni par la source)

Author response for "The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter ‐2 inhibitor, in type 2 diabetes"

Sae Im Jeong, Mu Seong Ban, Jun Gi Hwang, Min Kyu Park et autres

Author response for "Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study"

Ju‐Hyun An, Hansol Choi, Ji‐Soo Choi, Hyun‐Woo Lim et autres

Author response for "A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study"

Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee et autres

Author response for "Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study"

Ju‐Hyun An, Hansol Choi, Ji‐Soo Choi, Hyun‐Woo Lim et autres

Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects

Sukyong Yoon, Min Soo Park, Byung Hak Jin, Hyo-Bin Shin et autres

BACKGROUND: DWP16001, a sodium-glucose cotransporter-2 inhibitor, has shown promise for improving blood glucose control and facilitating weight loss. Co-administration with phentermine could enhance these effects. So, we aimed to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions of DWP16001 and phentermine. METHODS: …

kr (code pays fourni par la source)

Author response for "Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study"

Ju‐Hyun An, Hansol Choi, Ji‐Soo Choi, Hyun‐Woo Lim et autres

Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial

Ye Yang, Kyung Wan Min, Seok‐O Park, Kyung‐Soo Kim et autres

AIMS: The study aimed to evaluate and compare the efficacy and safety of enavogliflozin, a newly developed sodium-glucose cotransporter 2 inhibitor, with placebo in Korean patients with type 2 diabetes mellitus. MATERIALS AND METHODS: Patients with glycated haemoglobin (HbA1c) of 7.0-10.0%, entered …

kr, us (code pays fourni par la source)